Prenatal exposure to antiseizure medication polytherapy is associated with lower birthweight centiles and roughly 50 percent higher odds of poor foetal growth compared to monotherapy, according to a prospective international cohort study published in The Lancet Neurology. Researchers examined data from 15,893 offspring to evaluate how different treatment regimens and individual medicines impact pregnancy outcomes.
Polytherapy Exposure and Foetal Growth Risks
According to the study led by Piero Perucca and EURAP collaborators, analyzing 12,911 offspring exposed to monotherapy and 2,982 exposed to polytherapy revealed distinct growth differences. Prenatal exposure to multiple antiseizure medications correlated with a lower birthweight centile. The adjusted odds ratio for small for gestational age was 1.48, with a 95 percent confidence interval between 1.29 and 1.70. For severe small for gestational age, the adjusted odds ratio reached 1.49, while low birthweight stood at 1.50.
The risk appeared to compound as treatment regimens expanded. Offspring exposed to four simultaneous medications demonstrated substantially lower birthweight centiles than those receiving monotherapy.
Individual Antiseizure Medication Variances
The registry data showed that individual monotherapies carry varying associations with birthweight. When compared directly to lamotrigine, offspring exposed to topiramate, phenobarbital, oxcarbazepine, carbamazepine, valproic acid, and levetiracetam exhibited lower birthweight centiles.
Topiramate registered the largest difference, yielding an adjusted birthweight centile coefficient of −11.93. However, combinations did not follow a uniform pattern. Offspring exposed to carbamazepine combined with levetiracetam had a lower birthweight centile than those on lamotrigine monotherapy, whereas combinations of lamotrigine with either levetiracetam or valproic acid showed no significant difference compared to lamotrigine alone.
Did You Know?
The EURAP international registry is a prospective cohort study network tracking pregnancy outcomes in women with epilepsy across multiple countries to better understand the safety profiles of antiseizure treatments.
Clinical Implications for Pregnancy Management
According to the study authors, poor foetal growth requires evaluation alongside congenital malformations and neurodevelopmental impacts when assessing prenatal medication exposure. These findings inform preconception counselling and treatment selection, particularly when balancing seizure control with foetal development.
Because the research relied on an observational design, the data identifies associations rather than direct causation from individual drugs. Investigators emphasize that risk prediction models should account for specific drug differences and combinations to support personalized epilepsy management during pregnancy.
Frequently Asked Questions
What did the EURAP registry study find regarding antiseizure medications in pregnancy?
The study found that prenatal exposure to polytherapy was associated with a lower birthweight centile and roughly 50 percent higher odds of poor foetal growth measures compared to monotherapy.
Which antiseizure medication showed the largest difference in birthweight centile?
Topiramate monotherapy showed the largest difference, yielding an adjusted birthweight centile coefficient of −11.93 compared to lamotrigine.
Do these findings prove that specific medications directly cause poor foetal growth?
No. According to the researchers, the observational design identifies associations rather than establishing direct causation from individual medicines.
Stay Informed on Clinical Research
Subscribe to our newsletter for the latest updates on neurology, clinical trials, and perinatal health studies.
Keep reading